drugset / Trial / NCT00082628
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.
Timeline
- Start
- 2004-05-28
- Primary completion
- 2005-09-28
- Completion
- 2005-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 2 mg | Subcutaneous |
| Subject | Somatropin | Protein / enzyme biologic | 4 mg | Subcutaneous |